RDHL Redhill Biopharma Ltd. - Americ

10.54
+0.09  (0.86%)
Previous Close 10.45
Open 10.40
Price To book 3.29
Market Cap 134.35M
Shares 12,747,000
Volume 51,300
Short Ratio 1.54
Av. Daily Volume 58,359

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b to be initiated 1H 2017.
YELIVA
Prevention of mucositis in cancer patients undergoing therapeutic radiotherapy
Phase 1/2 trial initiation announced September 8, 2016. Announced that dosing has commenced - December 19, 2016.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Planned resubmission of NDA due 1H 2017.
RIZAPORT (RHB-103)
Migraine
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Interim efficacy analysis due 2Q 2017.
RHB-104 MAP US
Crohn’s disease
Phase 3 final data released March 2016. Additional Phase 3 trial planned to be initiated by April 2017.
RHB-105
H. pylori
Phase 3 top-line data due mid-2017.
BEKINDA -GUARD
Gastroenteritis
Phase 2a data released December 12, 2016.
RHB-104 CEASE-MS
Multiple sclerosis
Phase 2 top-line data due mid 2017.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer
Phase 2 to be initiated 2H 2016
YELIVA
Mucositis in cancer patients
Phase 1/2 trial amended to include Kaposi sarcoma patients. Trial due to resume in late 2016.
YELIVA
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. Blog Coverage Redhill Receives QIDP Fast-Track Designation from FDA for its Nontuberculous Mycobacteria Infections Combination Therapy
  2. RedHill Biopharma Provides 2017 Semi-Annual Business Update
  3. RedHill Biopharma Provides 2017 Semi-Annual Business Update
  4. RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections
  5. RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections
  6. RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection
  7. RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection
  8. RedHill Biopharma’s RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium
  9. RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management
  10. RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management
  11. RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference
  12. RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference
  13. RedHill Biopharma Announces New Research Collaboration with Aarhus University for Oncology Drug MESUPRON
  14. Blog Coverage RedHill Biopharma Signs Co-Promotion Agreement with Concordia and Announces Exercise of Underwriters Options
  15. RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium
  16. RedHill Biopharma Announces Exercise of Underwriters' Option
  17. RedHill Biopharma Announces Exercise of Underwriters’ Option
  18. RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal®
  19. RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal®
  20. Concordia International Corp. Announces Co-Promote Agreement for Donnatal®